English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 2 August 2023, 21:38 HKT/SGT
Share:
Kingworld Medicines Expects 1H Profit Increased By 35%-40%
Demonstrating Strong Business Performance and Competitive Strengths

HONG KONG, Aug 2, 2023 - (ACN Newswire) - Kingworld Medicines Group ("Kingworld Medicines" or the "Group", stock code: 01110.HK), a leading healthcare distribution company, announced a projected rise in profit for the first half of the fiscal year. Based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ending June 30, 2023, the Group anticipates a profit surge ranging from approximately 35% to 40% for the period, compared to the same period last year.

The Board attributes this profit increase to increased revenue and gross profit stemming from the distribution of imported branded pharmaceutical and healthcare products in China, with growth rates reaching approximately 30% to 35% and 15% to 20%, respectively. Additionally, the Group's share of profit from a joint venture saw a boost of approximately 55% to 60% compared to the same period last year. This surge is attributed to the market recovery after the COVID-19 pandemic control measures.

Kingworld Medicines is a company specializing in the distribution of imported branded pharmaceutical and healthcare products in China. The Group adeptly navigated post-pandemic market changes, propelling business expansion by leveraging its industry strengths.

Mr. Zhao Lisheng, Chairman of the Board of Kingworld Medicines Group, commented: "The Group's profit increase was mainly due to market recovery and the Group's employees' unremitting efforts, which adapted post-pandemic. The Group's strengths lie in its strong capabilities in distributing pharmaceutical and healthcare products and its acute insights into the market. Besides, the Group has achieved long-term steady growth by continuously improving efficiency and expanding its business."

Looking ahead, Kingworld Medicines Group will continue to focus on increasing market share, expanding business coverage, and improving efficiency to further enhance the company's profitability and market competitiveness.


Topic: Press release summary Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013  
Feb 5, 2026 17:42 HKT/SGT
Banle Group Hosts Inaugural ESG Forum with Industry Leaders, Pioneering Green Shipping Solutions Amid Global Decarbonization Push  
Feb 5, 2026 16:37 HKT/SGT
Annature Launches 21 CFR Part 11 Compliant Digital Signatures to Support FDA-Regulated Organisations  
Feb 5, 2026 13:00 HKT/SGT
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States  
Feb 5, 2026 12:54 HKT/SGT
Goldenstone Acquisition Limited (Ticker: GDST) Announces Intent to Merge with ESG Packaging Innovator Deluxe Technology Group, Targeting 2026 NASDAQ Listing  
Feb 5, 2026 12:53 HKT/SGT
SuperX Strengthens Japan Presence to Explore AI Data Center Projects with Local Partners  
Feb 5, 2026 11:00 HKT/SGT
Hitachi significantly expands exhibits at the "Hitachi Building Solutions Lab", a research facility for collaborative creation with customers  
Thursday, February 5, 2026 10:48:00 AM
Military Metals Drills 23.5 Meters of 3.3 g/t Gold Including 4.0 Meters of 10.52 g/t Gold and 1.9 Meters of 2.53% Antimony at Flagship Trojarova Project, Europe  
Feb 4, 2026 21:59 HKT/SGT
Japantastics Launches Global Curator Platform Bringing Japan Craftsmanship to the World  
Wednesday, February 4, 2026 9:00:00 PM
The 55-Point Gap: Measuring What Matters in Automotive Impact  
Wednesday, February 4, 2026 5:00:00 PM
More Press release >>
 Events:
More events >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575